196 related articles for article (PubMed ID: 26170629)
41. A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.
Sandhu SK; Papadopoulos K; Fong PC; Patnaik A; Messiou C; Olmos D; Wang G; Tromp BJ; Puchalski TA; Balkwill F; Berns B; Seetharam S; de Bono JS; Tolcher AW
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1041-50. PubMed ID: 23385782
[TBL] [Abstract][Full Text] [Related]
42. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer.
Bayliss TJ; Smith JT; Schuster M; Dragnev KH; Rigas JR
Expert Opin Biol Ther; 2011 Dec; 11(12):1663-8. PubMed ID: 21995322
[TBL] [Abstract][Full Text] [Related]
43. IL-6 and ovarian cancer--letter.
Locasale JW; Zeskind B
Clin Cancer Res; 2011 Dec; 17(24):7837; author reply 7838. PubMed ID: 22147939
[No Abstract] [Full Text] [Related]
44. A rapid and efficient in vivo method for determining the biologic efficacy of monoclonal antibodies in animal models of cancer.
Staquet K; Giles-Komar J
Hybridoma (Larchmt); 2006 Apr; 25(2):68-74. PubMed ID: 16704306
[TBL] [Abstract][Full Text] [Related]
45. Gene of the month: Interleukin 6 (IL-6).
Ataie-Kachoie P; Pourgholami MH; Richardson DR; Morris DL
J Clin Pathol; 2014 Nov; 67(11):932-7. PubMed ID: 25031389
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of interleukin-6 signaling with CNTO 328 enhances the activity of bortezomib in preclinical models of multiple myeloma.
Voorhees PM; Chen Q; Kuhn DJ; Small GW; Hunsucker SA; Strader JS; Corringham RE; Zaki MH; Nemeth JA; Orlowski RZ
Clin Cancer Res; 2007 Nov; 13(21):6469-78. PubMed ID: 17975159
[TBL] [Abstract][Full Text] [Related]
47. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo.
Trikha M; Zhou Z; Nemeth JA; Chen Q; Sharp C; Emmell E; Giles-Komar J; Nakada MT
Int J Cancer; 2004 Jun; 110(3):326-35. PubMed ID: 15095296
[TBL] [Abstract][Full Text] [Related]
48. Interleukin-6 signaling pathway in targeted therapy for cancer.
Guo Y; Xu F; Lu T; Duan Z; Zhang Z
Cancer Treat Rev; 2012 Nov; 38(7):904-10. PubMed ID: 22651903
[TBL] [Abstract][Full Text] [Related]
49. Pathogenic role of interleukin-6 in the development of sepsis. Part II: Significance of anti-interleukin-6 and anti-soluble interleukin-6 receptor-alpha antibodies in a standardized murine contact burn model.
Pallua N; Low JF; von Heimburg D
Crit Care Med; 2003 May; 31(5):1495-501. PubMed ID: 12771624
[TBL] [Abstract][Full Text] [Related]
50. A first-in-human study of conatumumab in adult patients with advanced solid tumors.
Herbst RS; Kurzrock R; Hong DS; Valdivieso M; Hsu CP; Goyal L; Juan G; Hwang YC; Wong S; Hill JS; Friberg G; LoRusso PM
Clin Cancer Res; 2010 Dec; 16(23):5883-91. PubMed ID: 20947515
[TBL] [Abstract][Full Text] [Related]
51. Naptumomab estafenatox: a new immunoconjugate.
Robinson MK; Alpaugh RK; Borghaei H
Expert Opin Biol Ther; 2010 Feb; 10(2):273-9. PubMed ID: 20053143
[TBL] [Abstract][Full Text] [Related]
52. Antibody drug conjugates - Trojan horses in the war on cancer.
Iyer U; Kadambi VJ
J Pharmacol Toxicol Methods; 2011; 64(3):207-12. PubMed ID: 21843648
[TBL] [Abstract][Full Text] [Related]
53. [Herceptin (trastuzumab)].
Yamashiro H; Toi M
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1173-6. PubMed ID: 17687197
[TBL] [Abstract][Full Text] [Related]
54. Success of bevacizumab trials raises questions for future studies.
Tuma RS
J Natl Cancer Inst; 2005 Jul; 97(13):950-1. PubMed ID: 15998941
[No Abstract] [Full Text] [Related]
55. A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.
Parihar R; Nadella P; Lewis A; Jensen R; De Hoff C; Dierksheide JE; VanBuskirk AM; Magro CM; Young DC; Shapiro CL; Carson WE
Clin Cancer Res; 2004 Aug; 10(15):5027-37. PubMed ID: 15297404
[TBL] [Abstract][Full Text] [Related]
56. Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges.
Teng F; Kong L; Meng X; Yang J; Yu J
Cancer Lett; 2015 Aug; 365(1):23-9. PubMed ID: 25980820
[TBL] [Abstract][Full Text] [Related]
57. [An overview of antibody therapy against cancer].
Taniguchi H; Imai K
Nihon Rinsho; 2012 Dec; 70(12):2087-92. PubMed ID: 23259378
[TBL] [Abstract][Full Text] [Related]
58. First results for agents targeting cancer-related inflammation.
Garber K
J Natl Cancer Inst; 2009 Aug; 101(16):1110-2. PubMed ID: 19671776
[No Abstract] [Full Text] [Related]
59. Avastin-Tarceva combination fails in lung cancer.
Jones D
Nat Biotechnol; 2009 Feb; 27(2):108-9. PubMed ID: 19204674
[No Abstract] [Full Text] [Related]
60. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer.
Taniguchi K; Karin M
Semin Immunol; 2014 Feb; 26(1):54-74. PubMed ID: 24552665
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
